Founded in 2013, BioAscent is a leading provider of integrated drug discovery services based at the former Organon / Merck Sharpe and Dohme (MSD) R&D site in Newhouse, Scotland. Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening (including HTS with our 125k diversity library), medicinal chemistry, synthetic chemistry, computational chemistry and full compound management services. Our team of expert scientists has experience of successfully working from assay development through to preclinical and clinical candidates across all biological target classes and major therapeutic indications. As part of its compound management service, BioAscent currently holds and manages over 1 million compounds for our customers, in both liquid and solid formats. Through the Compound Cloud service, the company provides on-demand access to an IP-free library of ~125,000 lead like compounds in screening-ready format. Since 2013, the BioAscent team has been responsible for:
100 biochemical and biophysical assays for drug discovery projects
50 hit validation/characterisation projects
30 hit-to-lead campaigns
80,000 screening plates delivered to our global customers/partners
